[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-arrhythmias\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-arrhythmias":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,79,104,137,160,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100494895","observational-study-of-cardiac-arrhythmias-during-treatment-with-btk-inhibitors-or-venetoclax-100494895",false,"NCT05724121","Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Currently receiving or planning to receive a BTKi or venetoclax.\n2. Male or female, aged 18 or older\n3. Stated willingness to comply with all study procedures and availability for the duration of the study\n4. Ability of subject to understand and the willingness to sign a written informed consent document\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Any acute cardiac condition including myocardial infarction or decompensated heart failure within the past 3 months\n2. Pregnancy or lactation- use of BTK inhibitors is contraindicated in pregnant or nursing individuals.","ALL","18 Years","110 Years",{"count":19,"type":20},135,"ESTIMATED","OBSERVATIONAL","Background:\n\nBruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart.\n\nObjective:\n\nTo identify and monitor the effects of BTKi on the heart.\n\nEligibility:\n\nPeople aged 18 and older currently receiving or planning to receive BTKi or venetoclax.\n\nDesign:\n\nParticipants who have not yet started BTKi will have 2 required clinic visits: 1 before they start taking BTKi, and 1 about 6 months later. Participants who are already taking BTKi will have 1 required visit.\n\nParticipants will undergo multiple tests:\n\nA physical exam, including collection of blood and saliva.\n\nA test that measures heart activity via stickers placed on the chest.\n\nA test that uses sound waves to capture images of the heart.\n\nAn exercise stress test that monitors heart activity and blood pressure while the participant works on a treadmill or stationary bike. Sound wave images of the heart may also be taken while the participant exercises.\n\nStress magnetic resonance imaging (MRI) may be done in place of an exercise test. Participants will lie on a table that slides into a tube. They will be given drugs to stress the heart while images are taken.\n\nParticipants may wear a device to monitor their heart at home.\n\nParticipants may have repeat visits if they develop heart symptoms or if they need to stop taking BTKi. They will have follow-up phone calls each year for up to 3 years.",[24,25,26,27,28,29],"Chronic Lymphocytic Leukemia (CLL)","Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia","Mantle Cell Lymphoma","Sudden Cardiac Death","Cardiac Arrhythmias","Hematologic Malignancies",[31,24,32,33,34,35],"SUDDEN CARDIAC DEATH","Ibrutinib Treatment","Atrial Fibrillation\u002FFlutter","Ventricular Arrhythmias","Natural History","RECRUITING","2026-07-01",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2023-03-01",{"date":44,"type":20},"2027-04-08",{"name":46,"class":47},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100642677","phase-4-the-clinical-outcomes-and-therapeutic-effects-in-patients-with-cardiac-implantable-electronic-device-detected-subclinical-and-clinical-atrial-fibrillation-100642677","NCT07649109","The Clinical Outcomes and Therapeutic Effects in Patients With Cardiac Implantable Electronic Device-detected Subclinical and Clinical Atrial Fibrillation.","National Tawan University Hospital","AHRE","Inclusion Criteria Age ≥18 years. Presence of a cardiac implantable electronic device (CIED), including permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device.\n\nDevice-detected atrial high-rate episodes (AHREs) lasting ≥6 minutes and \\\u003C24 hours.\n\nAbility to provide written informed consent. Willingness and ability to comply with study procedures and follow-up visits. Exclusion Criteria Prior diagnosis of clinical atrial fibrillation, atrial flutter, or atrial tachycardia requiring treatment.\n\nDevice-detected AHRE ≥24 hours before enrollment. Current treatment with class I or class III antiarrhythmic drugs for atrial arrhythmias.\n\nPrevious catheter ablation for atrial fibrillation or atrial flutter. Planned catheter ablation within the next 3 months. Contraindication to rhythm-control therapy as determined by the treating physician.\n\nLife expectancy less than 1 year. Severe comorbid illness that may interfere with study participation or follow-up.\n\nPregnancy or breastfeeding. Participation in another interventional clinical trial that may affect study outcomes.",{"count":58,"type":20},450,"INTERVENTIONAL",[61],"PHASE4","Atrial high-rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs) are associated with an increased risk of progression to clinical atrial fibrillation (AF), stroke, heart failure, and mortality. However, optimal management strategies for patients with AHREs lasting between 6 minutes and 24 hours remain uncertain. Current guidelines recommend risk factor modification, but the role of early rhythm-control therapy in preventing AHRE progression has not been well established.\n\nThis prospective, randomized, open-label study aims to evaluate whether a rhythm-control strategy combined with optimal risk factor management can reduce progression to sustained AHREs (≥24 hours) or clinical AF compared with optimal risk factor management alone in patients with device-detected AHREs. Eligible participants with CIED-detected AHREs lasting 6 minutes to 24 hours and without prior clinical AF will be randomly assigned to either a rhythm-control group or a usual-care group. The primary endpoint is progression to AHRE duration ≥24 hours or documented clinical AF. Secondary endpoints include stroke, systemic embolism, heart failure hospitalization, cardiovascular death, and all-cause mortality.",[64,28],"Subclinical Atrial Fibrillation",[66,67,68],"Atrial High-Rate Episodes (AHRE)","Cardiac Implantable Electronic Device","Early Rhythm Control","2026-06-11",{"date":71,"type":40},"2026-06-16",{"date":73,"type":40},"2025-10-01",{"date":75,"type":20},"2027-12-31",{"name":77,"class":78},"National Taiwan University Hospital","OTHER",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100575454","viewflex-x-ice-first-in-human-study-100575454","NCT06772493","ViewFlex X ICE First-in-Human Study","ViewFlex X FIH","Inclusion Criteria:\n\nA patient will be eligible for clinical trial participation if they meet the following criteria:\n\n1. Able and willing to provide written informed consent prior to any clinical investigation-related procedure.\n2. Plans to undergo any EP procedure utilizing ICE\n3. At least 18 years of age\n\nExclusion Criteria:\n\nA patient will be excluded from enrollment in the study if they meet any of the following criteria:\n\n1. Subject is currently participating in another clinical trial with an active treatment arm or has participated in such a clinical trial within 30 days prior to enrollment that may interfere with this clinical trial without pre-approval from this study Sponsor\n2. Implanted mechanical mitral or tricuspid valve replacement\n3. Implanted intracardiac device within 30 days\n4. Pregnant or nursing\n5. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.",{"count":87,"type":20},500,"This prospective, acute, first-in-human, non-significant risk study is intended to evaluate a modified version of the ViewFlex X ICE Catheter, Sensor Enabled (ViewFlex X SE) and ViewMate Multi Ultrasound Console (VMM) ICE data integration with the EnSite X EP System (hereafter referred to as the ViewFlex X ICE System).",[28],[91,92],"Intracardiac Echocardiography","cardiac electrophysiology","2026-05-30",{"date":95,"type":40},"2026-06-02",{"date":97,"type":40},"2024-12-16",{"date":99,"type":20},"2026-06",{"name":101,"class":102},"Abbott Medical Devices","INDUSTRY",8,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":15,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100507694","ai-powered-ecg-analysis-using-willem-software-in-high-risk-cardiac-patients-willem-100507694","NCT05890716","AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)","Evaluation of Electrocardiographic Data From High-risk Cardiac Patients Using Willem™ Cardiologist-level Artificial Intelligence Software. WILLEM Trial.","WILLEM","Inclusion Criteria:\n\n* Patient presenting relevant cardiac arrhythmias and cardiac patterns (including supraventricular tachycardias, abnormal ECG patterns, ventricular tachycardias, ventricular fibrillation, pulseless electrical activity or asystole among others) that have been recorded with at least one short-term ECG medical device according to guidelines with ≥1 signal-channel.\n* Patient with suspected or diagnosed acute\u002Fchronic cardiac diseases (including patients with heart failure, patients with history of cardiac arrhythmias, patients with probable coronary artery diseases, patients with cardiomyopathies, patients with pacemakers or implantable cardioverter-defibrillators (ICD), patients with indication of pacemaker or ICD in current or short-term phase, patients participating in other interventional clinical investigation, patients with hemodynamic instability or acute coronary syndromes, pregnant patients, patients with cancer and chemotherapy, patients with life-expectancy lower than 24 months, patients with in or out-of-hospital cardiac arrest with ventricular fibrillation as first documented rhythm).\n* At least one ECG tracing that can be exported in raw data.\n* Signed informed consent. Patients unable to consent, it will be requested to an authorized relative.\n\nExclusion Criteria:\n\n* Unwillingness or inability to sign study written informed consent.\n* Unavailable or suboptimal quality of the electrocardiographic signal in raw data.",true,"4 Years",{"count":115,"type":20},5342,"WILLEM is a multi-center, prospective and retrospective cohort study.\n\nThe study will assess the performance of a cloud-based and AI-powered ECG analysis platform, named Willem™, developed to detect arrhythmias and other abnormal cardiac patterns. The main questions it aims to answer are:\n\n1. A new AI-powered ECG analysis platform can automatice the classification and prediction of cardiac arrhythmic episodes at a cardiologist level.\n2. This AI-powered ECG analysis can delay or even avoid harmful therapies and severe cardiac adverse events such as sudden death.\n\nThe prerequisites for inclusion of patients will be the availability of at least one ECG record in raw data, along with patient clinical data and evolution data after more than 1-year follow-up.\n\nCardiac electrical signals from multiple medical devices will be collected by cardiology experts after obtaining the informed consent. Every cardiac electrical signal from every subject will be reviewed by a board-certified cardiologist to label the arrhythmias and patterns recorded in those tracings. In order to obtain tracings of relevant information, \\>95% of the subjects enrolled will have rhythm disorders or abnormal ECG's patterns at the time of enrollment.",[118,119,28,27],"Cardiomyopathies","Cardiac Arrest",[121,122,123,124,125,126],"Artificial intelligence","Cardiac arrhythmias","Heart disease","Cardiac electrical signals","Electrocardiogram","Electrogram","2026-03-30",{"date":129,"type":40},"2026-04-03",{"date":131,"type":40},"2023-04-04",{"date":133,"type":20},"2026-11",{"name":135,"class":102},"Idoven 1903 S.L.",14,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":48},"100594550","bad-berka-heart-rhythm-registry-of-patients-with-or-at-risk-of-arrhythmias-treated-at-heart-center-bad-berka-100594550","NCT07020910","Bad Berka Heart Rhythm Registry of Patients With or at Risk of Arrhythmias Treated at Heart Center Bad Berka","The Bad Berka Heart Rhythm Registry (2B2R) is a Prospective, Single-center Observational Cohort Evaluating Safety, Efficacy, and Outcomes in Patients Undergoing Arrhythmia Therapy or CIED Implantation at the Heart Center Bad Berka","2B2R","Inclusion Criteria:\n\n* Age ≥18 years\n* At risk of or with documented cardiac arrhythmia undergoing medical or interventional therapy at the Heart Center Bad Berka\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent\n* Participation in another interventional trial that precludes registry inclusion",{"count":146,"type":20},5000,"The Bad Berka Heart Rhythm Registry (2B2R) is a prospective, single-center observational cohort designed to systematically collect and analyze data of patients undergoing cardiac arrhythmia therapy as well as implantation of cardiac electronic devices (CIEDs) at the Heart Center Bad Berka.\n\nThe register aims to evaluate procedural safety, acute and long-term efficacy, and clinical outcomes across a broad spectrum of arrhythmias and interventional strategies, including novel technologies such as pulsed field ablation (PFA) and conduction system pacing. The registry is intended to generate real-world evidence to support clinical decision-making, identify predictors of outcomes, and contribute to quality assurance and innovation in the field of cardiac electrophysiology.",[28],[150],"Arrhythmia","2025-06-12",{"date":153,"type":40},"2025-06-13",{"date":155,"type":40},"2024-08-01",{"date":157,"type":20},"2034-08-01",{"name":159,"class":78},"Zentralklinik Bad Berka",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":166,"targetDuration":168,"studyType":21,"phases":4,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":48},"100585126","utility-of-gene-test-analysis-for-diagnosis-prognosis-and-treatment-of-patients-with-genetic-arrhythmic-heart-disease-the-arrhythmic-gene-heart-100585126","NCT06898307","Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: the ARRHYTHMIC GENE-HEART","Inclusion Criteria:\n\n* Patients evaluated at the Cardiogenetic Center of the University of Ferrara in Ferrara, Italy.\n* Having a proven cardiogenetic disease\n\nExclusion Criteria:\n\n* Refuse to provide informed consents\n* Patients not having a cardiogenic disease",{"count":167,"type":20},200,"10 Years","The goal of this observational study is to enroll all patients evaluated at the specialized Cardiogenetic Center within the Cardiology Department of the University of Ferrara, Italy. The primary aim of the registry is to collect comprehensive clinical, genetic, and electrophysiological data from individuals with suspected or confirmed arrhythmogenic conditions. By systematically documenting patient demographics, family history, clinical presentations, diagnostic findings, and treatment outcomes, the registry seeks to enhance our understanding of the genetic basis and clinical implications of genetically driven arrhythmias and systemic syndromes. This registry will facilitate long-term follow-up of enrolled patients to assess the natural history of arrhythmogenic disorders and the effectiveness of various therapeutic interventions. Additionally, it aims to identify potential risk factors associated with adverse outcomes, such as sudden cardiac death or major arrhythmic events.",[171,172,28,173,174],"Genetic Disease","Cardiac Disease","Genetic Disorder","Cardiology",[176],"Cardiogenetic","2025-03-26",{"date":179,"type":40},"2025-03-27",{"date":181,"type":40},"2017-11-01",{"date":183,"type":20},"2035-11-01",{"name":185,"class":78},"University Hospital of Ferrara",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":48},"100341718","japanese-catheter-ablation-registry-100341718","NCT03729232","Japanese Catheter Ablation Registry","J-AB","Inclusion Criteria:\n\n* Patients treated with catheter ablation in Japan\n\nExclusion Criteria:\n\n* Patients who refused to consent",{"count":194,"type":20},400000,"Japanese Cather Ablation (J-AB) Registry is a voluntary nationwide registry, performed by Japanese Heart Rhythm Society, collaborated with the National Cerebral and Cardiovascular Center. The objectives of this registry are to observe and describe developments in the catheter ablation treatment of arrhythmia in Japan and to provide reliable information on the type of activity performed and the facilities available in Japanese arrhythmia units.",[197,28],"Catheter Ablation",[197,28,199,200,201],"Registry","Complication","REDCap","2023-11-09",{"date":204,"type":40},"2023-11-13",{"date":206,"type":40},"2017-07-01",{"date":208,"type":20},"2030-03-31",{"name":210,"class":78},"National Cerebral and Cardiovascular Center, Japan"]